Predict your next investment

HEALTHCARE | Biotechnology
silverbacktx.com

See what CB Insights has to offer

Founded Year

2016

Stage

IPO | IPO

Total Raised

$211M

Date of IPO

12/4/2020

Market Cap

0.25B

Stock Price

7.19

About Silverback Therapeutics

Silverback Therapeutics is a biotechnology company that develops a pipeline of systemically delivered, locally active therapies that can be administered to patients. The active therapies only act at the sites of disease, sparing healthy tissues from unwanted side effects.

Silverback Therapeutics Headquarter Location

500 Fairview Ave N Suite 600

Seattle, Washington, 98109,

United States

206-456-2900

Latest Silverback Therapeutics News

ROSEN, GLOBALLY RESPECTED INVESTOR COUNSEL, Encourages Silverback Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – SBTX

Nov 27, 2021

New York, New York, UNITED STATES NEW YORK, Nov. 26, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Silverback Therapeutics, Inc. (NASDAQ: SBTX): (1) pursuant and/or traceable to the registration statement and prospectus issued in connection with the Company’s December 3, 2020 initial public offering (“IPO”); and/or (2) between December 3, 2020 and September 10, 2021, inclusive (the “Class Period”), of the important January 4, 2022 lead plaintiff deadline. SO WHAT: If you purchased Silverback securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the Silverback class action, go to http://www.rosenlegal.com/cases-register-2200.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 4, 2022. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers. DETAILS OF THE CASE: According to the lawsuit, the IPO documents featured and defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Silverback’s lead product candidate SBT6050 (a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody that targets tumors, such as breast, gastric, and non-small cell lung cancers) was less effective than the Company had represented to investors; (2) accordingly, the Company had overstated SBT6050’s commercial and/or clinical prospects; and (3) as a result, the IPO documents and defendants’ public statements throughout the Class Period were materially false and/or misleading and failed to state information required to be stated therein. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the Silverback class action, go to http://www.rosenlegal.com/cases-register-2200.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm , on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/ . Attorney Advertising. Prior results do not guarantee a similar outcome. -------------------------------

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Silverback Therapeutics

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Silverback Therapeutics in 1 CB Insights research brief, most recently on Mar 24, 2020.

Expert Collections containing Silverback Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Silverback Therapeutics is included in 1 Expert Collection, including Biopharmaceuticals.

B

Biopharmaceuticals

14,140 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Silverback Therapeutics Patents

Silverback Therapeutics has filed 16 patents.

The 3 most popular patent topics include:

  • Immunology
  • Immune system
  • Radiation therapy
patents chart

Application Date

Grant Date

Title

Related Topics

Status

2/19/2021

11/23/2021

Monoclonal antibodies, Immune system, Immunology, Clusters of differentiation, Experimental cancer drugs

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

2/19/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

11/23/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Monoclonal antibodies, Immune system, Immunology, Clusters of differentiation, Experimental cancer drugs

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Silverback Therapeutics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Silverback Therapeutics Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.